RESMED INC 8-K

What Happened
ResMed Inc. filed a Form 8-K on July 7, 2026 to announce that on June 30, 2026 it entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners for $490 million in cash (subject to closing adjustments and regulatory approvals). The company said the deal is expected to close in the first quarter of ResMed’s fiscal 2027, and that transition services agreements (TSAs) with Frazier are expected to largely offset stranded costs in the first year after closing. ResMed plans to use net proceeds to return capital to shareholders (including an accelerated share repurchase, or ASR) and for general corporate purposes.

Key Details

• Agreement date: June 30, 2026; press release furnished July 7, 2026.
• Purchase price: $490 million all-cash, subject to certain closing adjustments and approvals.
• MatrixCare FY2026 (preliminary): ~ $220 million revenue and ~ $55 million non-GAAP operating profit.
• Other impacts: ResMed’s recent Noctrix acquisition is expected to add ~ $30 million of revenue and reduce non-GAAP diluted EPS by ~ $0.20 in fiscal 2027.
• Guidance/next steps: ResMed reiterated several FY2026 outlook items and will provide full FY2027 guidance on its August 6, 2026 earnings call.

Why It Matters
This is a material divestiture of ResMed’s long‑term care software business that removes ~ $220M of annual revenue but also frees cash (~$490M) that the company intends to return to shareholders. Investors should note the near‑term financial effects highlighted by ResMed: estimated FY2026 MatrixCare contribution, expected first‑year TSA offsets for stranded costs, the Noctrix acquisition’s revenue and EPS impact in FY2027, and an upcoming FY2027 outlook on August 6, 2026. These items are relevant for revenue mix, reported/non‑GAAP profitability and capital allocation (including planned share repurchases).